2-(4-(Dibenzo[b,d]furan-4-yl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 97%, 5g

2,5,6-Trichloropyrimidin-4-amine, 95.0%, 5g

3,3-Diphenyl-3H-benzo[f]chromene, 95.0%, 25g

(2S,4S)-1-(tert-Butoxycarbonyl)-4-(trifluoromethyl)pyrrolidine-2-carboxylic acid, 95.0%, 5g

5-Bromo-1-methylpyrimidine-2,4(1h,3h)-dione, 97%, 5g

Reaktionsgefäße PP mit Schraubdeckel, steril, freistehend, 1,5 ml, 1000 Stück

Tert-butyl (S)-(4-amino-1-hydroxy-4-oxobutan-2-yl)carbamate, 95+%, 250mg

Thalidomide-O-PEG4-azide, 250mg

4-Chloro-N-(furan-2-ylmethyl)aniline, 95%, 10g

1-Methyl-2-nitro-3-(trifluoromethyl)benzene, 95.0%, 1g

2-Hydroxypyridine 1-oxide, 99.0%, 500g

Ethyl 2,6-dimethylbenzoylformate, 97.0%, 100mg

5,7-Dichloro-2-(methylthio)thiazolo[4,5-d]pyrimidine, 95.0%, 250mg